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Background

Results

Ø In cancers like glioblastoma, a grade IV astrocytoma with 22% five-year survival rate, there is
Ø With both assay types, HEX showed an (IC50) of ~1100 nM-1300 nM against ENO-/homozygous deletions of the 1p36 tumor suppressor locus (Figure 1) resulting in the
D423 cells while the ENO1 rescue cells showed essentially no sensitivity to HEX.
concomitant deletion of the glycolytic enzyme gene, ENO1 (encoding enolase 1)
Ø These values are in line with previous observations using crystal violet assays.
Ø Collateral lethality therapies capitalize on the “cancer-specific metabolic
Ø Matrigel coating increased initial adherence of cells but failed to mitigate assay
vulnerabilities’’(Muller et al), 2020) arising from the deletion of genes neighboring tumor
detachment. Additionally, TMZ showed an IC50 of 628.2 uM against ENO-/- D423
suppressors. The two enolase paralogs, ENO1 and ENO2, are essential in the glycolytic
cells and 1940 uM against ENO1+/- D502 cells
pathway given their role in the catalytic conversion of 2-phosphoglycerate (2 PG) to
phosphoenolpyruvate and this is what HEX targets.
A
B
Ø In this work, the inhibitory concentration (IC50) of HEX was re-determined on glioblastoma cells
with different ENO1 deletions using different viability assays and combined with a standardof-care glioblastoma drug, temozolomide (TMZ), to assess any synergistic effects.
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Method

Ø Cell culture experiments to test both HEX and TMZ sensitivity were performed in multiple
glioma cell lines with two different cell viability assays.
Ø Glioma cell lines with different ENO1 status (D423: ENO-/-; D423 ENO1 rescue; U343:
ENO1+/-; LN319: ENO1+/+; D502: ENO1+/- ) were treated for 5 days and subjected to a
sulfrhodamine B (SRB) assay and MTT assay: Cell viability via the SRB and MTT assay
uses total protein content and cell metabolic activity, respectively.
Ø The cell binding substrate Matrigel ® was also tested for its ability to better adhere cells that
detach during the assays.
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Figure 2: (A) HEX Kill curves generated from an MTT assay after
incubation with HEX on ENO1, D502 and D423 cell lines; (B) HEX Kill
curves generated from an SRB Assay after incubation with HEX on
ENO1, LN 319, U343 and D423 cell lines; (C) HEX kill curves generated
from an SRB assay after incubation with HEX on LN 319, ENO1, D423
and U343 cell lines. (D) HEX Kill curves generated from an SRB assay
after incubation with HEX on ENO1 and D502 cell lines

Conclusions

Ø HEX is effective against ENO1-deleted cells leaving wild type cells unaffected.
Ø TMZ, on the other hand had little effect, in cell culture.
Ø HEX needs to be further assessed as a combo treatment with TMZ for glioma
treatment.
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Figure 1 (A) Collateral lethality: a therapeutic strategy that capitalizes on the “cancerspecific metabolic vulnerabilities’’ arising from the deletion of passenger genes
(B) A schematic of the glycolytic pathway, with the reaction of interest emboldened. This
is the reaction HEX targets and inhibits.

